According to the research report titled ‘Asia Pacific Antiviral Drugs Market By Type, By Drug Class, By Indication, By Age Group, Research Report, Country Outlook Price Trends, Growth Prospects, Competitive Industry Share & Forecasts, 2021 – 2027’, available with Market Study Report, Asia Pacific antiviral drugs market is likely to witness stellar growth over the period of 2021-2027.
 

High occurrence of infectious diseases, rising cases of HAIs (hospital acquired infections) and increasing number of patients with HIV AIDS are some of the key factors fueling Asia Pacific antiviral drugs market. Growing elderly population and surging number of pipeline antivirals for HIV treatment, and the widespread COVID-19 outbreak in Australia, China, and India have also augmented the demand for antivirals in the region.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3736396/
 

In terms of drug class, the report states that reverse transcription inhibitors segment held 40% market share in the year 2020 and is likely to generate commendable returns in the subsequent years. Rising prevalence of infectious diseases, high effectiveness in managing and treating HIV, and high R&D investments are fueling the segmental share.
 

On the other hand, protease inhibitors segment accounted for 18% share in Asia Pacific antiviral drugs market and is deemed to showcase considerable growth through 2027. This drug class has been gaining significant recognition due to its high efficacy as a therapy drug. In addition, rising R&D activities will further impel the demand for protease inhibitors in the ensuing years.
 

As per indication, the report cites that HIV AIDS segment generated revenues worth USD 3.2 billion for Asia Pacific antiviral drugs market in 2020, primarily due to inflow of investments and rising cognizance regarding availability of various treatment therapies.
 

Moving on to type, the generic segment accounted for USD 1.5 billion in the year 2020 and is predicted to expand significantly during the forecast duration. This explosive growth can be attributed to increasing awareness regarding availability of generic therapeutics and supportive regulatory outlook towards providing affordable treatment options.
 

By age group, the adult segment seized 30% market share in the year 2020, primarily due to rising production of antiviral drugs for the adult age group.
 

From the geographical point of view, India antiviral drugs industry size is anticipated to surpass USD 1.2 billion by the year 2027, owing to improving healthcare infrastructure, escalating investments, as well as rising cases of COVID-19 and HIV AIDS.
 

China, on the other hand, captured 16% market share in 2020 and is poised to amass notable gains in the coming period. Surging government investments and rising R&D activities will provide lucrative growth avenues for the market majors in China.
 

Speaking of which, the major companies operating in Asia Pacific antiviral drugs market are Viatris Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Aurobindo Pharma Limited, Bristol Myers Squibb, Merck & Co. Inc., AbbVie, GlaxoSmithKline plc, Johnson & Johnson, and Gilead Sciences Inc. among others.